๐จ New paper out in Cardiovascular Revascularization Medicine ๐จ
We analyzed 469,175 urban TAVR hospitalizations from 2016-2022.
The signal was clear:
๐ซ Black and Hispanic patients had higher cardiometabolic burden
โ ๏ธ Hispanic patients had higher mortality, MACE, AKI/dialysis, mechanical ventilation, transfusion, and cost
โ ๏ธ Black patients had higher MACE, AKI, prolonged LOS, and CPR
โ Stroke outcomes were similar across groups
The takeaway: TAVR has advanced dramatically, but equity in outcomes still needs to catch up.
Proud of our team and grateful to everyone involved.
https://t.co/1W52C1fLI3
#TAVR #Cardiology #HealthEquity #StructuralHeart #MedTwitter
This is a tremendous honor. Virgil Brown has been an outstanding researcher, clinician, educator and leader @nationallipid This award is a tribute to my mentors, trainees, colleagues and collaborators @BCMHeart@vijay_nambi@LaylaAbushamat@virani_md
Presented at #ACC26:
Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results: https://t.co/q0vNdAoJJL
Editorial: Paving the Road toward Targeted Lipid Lowering https://t.co/zUwmo0r0n4
@ACCinTouch
"I hope you take time to explore the city, eat some heart-healthy beignets (!), and enjoy all that the Big Easy has to offer โ just donโt miss your presentation time!" - #ACCPresident@ChrisKramerMD
New data from 10,421 patients with metabolic syndrome: the C-reactive protein-triglyceride-glucose index (CTI) outperformed 23 cardiometabolic markers โ including TyG, CRP, NLR, and non-HDL-C โ as a predictor of CV mortality.
Patients in the highest CTI quartile had a 60% higher risk of CV death.
Integrating inflammation + metabolic stress into a single index may be the key to better risk stratification in MetS.
๐ Journal of Clinical Lipidology (2026)
#Cardiology #MetabolicSyndrome #CVDRisk #Inflammation #PreventiveCardiology
https://t.co/CAWw1R35q7
Here, I discuss why low blood pressure (BP) should not delay heart failure (HF) treatment.
This podcast is part of the Managing HF Across the Spectrum: From Recognizing Symptoms to Implementing Appropriate Treatment initiative, supported by Bayer AG.
https://t.co/1bpOrmoUT7
Donโt miss out! ๐ฌ๐ซCardioTwitter! โAt #ACCMidEast presented how the Triglyceride-Glucose Index predicts CV mortality in metabolic syndrome. Important insights into precision risk stratification in diverse populations. ๐ฌโค๏ธ the team is here from Miami ! ๐ด@ElajamiMohamad